Fig. 2: ROR1 signaling and targeted therapies for tumor cell inhibition.
From: Therapeutic advances in the targeting of ROR1 in hematological cancers
The WNT binding to FZD domain triggers downstream signals that support proliferation, stimulate migration and tumor development by inhibiting programed cell death. Targeted therapies, such as CAR T, BiTEs, mAbs and other compounds bind the external subunits of ROR1 and further inhibit critical signaling pathways that control tumor cell survival, proliferation, migration and development (Created with BioRender.com).
